Shares of Alector, Inc. (NASDAQ:ALEC - Get Free Report) have been assigned a consensus rating of "Hold" from the seven brokerages that are currently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $5.10.
A number of equities analysts recently issued reports on ALEC shares. HC Wainwright assumed coverage on Alector in a report on Friday, November 6th. They issued a "strong-buy" rating for the company. UBS Group reissued a "neutral" rating and set a $1.50 price objective on shares of Alector in a report on Tuesday, October 6th. Wells Fargo & Company assumed coverage on shares of Alector in a research report on Friday, November 13th. They set an "overweight" rating and a $7.00 price objective for the company. Wall Street Zen upgraded shares of Alector from a "hold" rating to a "buy" rating in a research report on Saturday, November 7th. Finally, Morgan Stanley upped their target price on shares of Alector from $2.00 to $3.00 and gave the company an "underweight" rating in a report on Tuesday, October 6th.
Get Our Latest Stock Analysis on ALEC
Alector Stock Performance
NASDAQ:ALEC opened at $2.34 on Friday. The stock has a 50-day simple moving average of $2.09 and a 200-day simple moving average of $2.06. The stock has a market cap of $348.38 million, a P/E ratio of 6.69, a P/E/G ratio of 0.16 and a beta of 0.61. Alector has a 1 year low of $1.09 and a 1 year high of $2.84.
Alector (NASDAQ:ALEC - Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported $1.11 earnings per share for the quarter, topping the consensus estimate of ($0.23) by $1.34. The business had revenue of $162.87 million for the quarter, compared to analyst estimates of $2.19 million. Alector had a return on equity of 112.21% and a net margin of 23.87%. On average, equities research analysts predict that Alector will post 0.68 EPS for the current year.
Insiders Place Their Bets
In related news, CEO Arnon Rosenthal sold 72,606 shares of the business's stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $2.66, for a total value of $193,131.96. Following the completion of the sale, the chief executive officer directly owned 2,294,600 shares of the company's stock, valued at $6,103,636. The trade was a 3.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Neil Berkley sold 29,251 shares of the company's stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $2.66, for a total transaction of $77,807.66. Following the completion of the transaction, the chief financial officer owned 350,649 shares of the company's stock, valued at $932,726.34. This represents a 7.70% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 111,303 shares of company stock worth $295,633 over the last ninety days. Insiders own 8.30% of the company's stock.
Institutional Trading of Alector
Hedge funds and other institutional investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. lifted its stake in Alector by 82.4% in the third quarter. Goldman Sachs Group Inc. now owns 791,601 shares of the company's stock valued at $1,464,000 after buying an additional 357,726 shares during the last quarter. Utah Retirement Systems boosted its holdings in shares of Alector by 13.3% in the third quarter. Utah Retirement Systems now owns 174,862 shares of the company's stock valued at $323,000 after acquiring an additional 20,572 shares during the period. Marshall Wace LLP grew its position in shares of Alector by 62.7% during the third quarter. Marshall Wace LLP now owns 973,761 shares of the company's stock worth $1,801,000 after acquiring an additional 375,202 shares during the last quarter. Empowered Funds LLC purchased a new position in shares of Alector during the third quarter worth approximately $213,000. Finally, Russell Investments Group Ltd. grew its position in shares of Alector by 8.2% during the third quarter. Russell Investments Group Ltd. now owns 106,614 shares of the company's stock worth $197,000 after acquiring an additional 8,118 shares during the last quarter. Institutional investors and hedge funds own 85.83% of the company's stock.
About Alector
(
Get Free Report)
Alector, Inc. is a biotechnology company based in South San Francisco, California, that develops investigational therapies for neurodegenerative diseases. Its research focuses on the role of the immune system in the brain and how immune pathways may be used to address disease processes. The company's approach draws on human genetics and immunology to identify potential therapeutic targets. Its research has included programs targeting progranulin and TREM2, proteins associated with brain health and neurodegenerative disease.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Alector, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alector wasn't on the list.
While Alector currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.